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Abstract
We present advancements in microfluidic technology for rapid detection of as few as ten 
rickettsial organisms in complex biological samples. An immuno-reactive filter, macroporous 
polyacrylamide monolith (PAM), fabricated within a microfluidic channel enhances solid-phase 
immuno-capture, staining and detection of targeted bacteria. Bacterial cells in samples flowing 
through the channel are forced to interact with the PAM filter surface due to size exclusion, 
overcoming common transport and kinetic limitations for rapid (minutes), high-efficiency 
(~100%) capture. In the process, targeted cells in sample volumes of 10 μl to >100 μl are 
concentrated within a sub-50 nl region at the PAM filter edge in the microchannel, thus 
concentrating them over 1,000-fold. This significantly increases sensitivity, as the hydrophilic 
PAM also yields low non-specific immuno-fluorescence backgrounds with samples including 
serum, blood and non-targeted bacteria. The concentrated target cells are detected using 
fluorescently-labeled antibodies. With a single 2.0 × 2.0 × 0.3 mm PAM filter, as few as 10 
rickettsial organisms per 100 μl of lysed blood sample can be analyzed within 60 min, as 
compared to hours or even days needed for conventional detection methods. This method is highly 
relevant to rapid, multiplexed, low-cost point of care diagnostics at early stages of infection where 
diagnostics providing more immediate and actionable test results are needed to improve patient 
outcomes and mitigate potential natural and non-natural outbreaks or epidemics of rickettsial 
diseases.
Keywords
Blood borne bacteria detection; microfluidic device; point-of-care diagnostic assay; 
polyacrylamide monolith; macroporous monolith filter; Rickettsia detection
*
 Corresponding author, PO Box 969, Mail Stop 9291, 7011 East Ave., Sandia National Laboratories, Livermore, CA 94551, USA. 
Phone number: (925)294-6291 ahatch@sandia.gov. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Biosens Bioelectron. Author manuscript; available in PMC 2016 January 14.
Published in final edited form as:
Biosens Bioelectron. 2014 April 15; 54: 435–441. doi:10.1016/j.bios.2013.11.012.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
1. Introduction
The ability to accurately diagnose potentially lethal infectious diseases at or even before 
their early symptomatic stages of disease remains a high priority due to risks of natural or 
unnatural outbreaks or epidemics. For the most threatening diseases, diagnostic tests are 
largely limited to confirmatory use because the time needed for a lab diagnosis test is too 
long for point-of-care therapeutic intervention. More immediate, actionable test methods are 
needed for early diagnosis. As one of the most dangerous bacteria that can cause life-
threatening diseases in humans, Rickettsial bacteria are an endemic problem in regions 
across the globe, and attempts to develop a rickettsiae-based bioweapon have also been 
documented (Azad 2007). Historically, rickettsiae have been divided into typhus group (TG) 
and spotted fever group (SFG). The former only has two members, namely R. prowazekii 
and R. typhi, the agents of epidemic and endemic typhus, respectively. On the other hand the 
SFG has several members including R. rickettsii and R. conorii, the agents of Rocky 
Mountain spotted fever and other spotted fevers in the Americas and Mediterranean spotted 
fever, respectively (Nyka 1950). If prompt and accurate diagnosis is rendered, rickettsial 
infections can be successfully treated using early and adequate antibiotic therapy. The drug 
of choice for rickettsial infections is doxycycline, followed by other tetracyclines. 
Unfortunately, these antibiotics are seldom used as empiric therapy in clinical settings for 
other undifferentiated febrile illnesses. In fact, some of the antimicrobial agents such as 
sulfonamides used in the clinical setting can worsen the clinical course of human 
rickettsioses. (Chapman 2006; Moody and Chiodini 2000). The acute phase of all 
rickettsioses occurs mostly as an undifferentiated febrile illness difficult to distinguish from 
other more common febrile conditions, leading to the use of ineffective antimicrobial 
therapy which eventually leads to either a fatal outcome or a more prolonged and severe 
clinical course (Chapman 2006). Current diagnostics primarily serve as confirmatory 
testsafter treatment choices have been made (Chapman 2006; Moody and Chiodini 2000). 
To be most useful, point-of-care diagnostic assays for rickettsial diseases must be rapid 
(sample-to-answer time <1 hr), highly sensitive, specific and affordable.
A number of technical challenges must be addressed to provide actionable results in time to 
support treatment decisions. The current gold standard is detection of rising serum antibody 
titers in paired sera (acute and convalescent samples obtained in at least a two weeks 
interval) by indirect immunofluorescence antibody (IFA) assay. However, this technique has 
a low clinical sensitivity during the acute phase and therefore appropriate therapeutic 
selections cannot be made timely. We focus instead on capturing rickettsial organisms using 
sandwich immunoassays with antibodies raised against R. conorii and R. typhi. The ultimate 
goal is to detect circulating rickettsial organisms in human blood during the acute phase of 
the disease. Existing antigen-capture or direct pathogen test methods are low to moderately 
sensitive and can be lengthy and costly, and usually require biohazard safety level 3 (BSL-3) 
facilities and highly trained personnel. Immunohistochemical (IHC) staining of antigens in 
skin biopsy specimens (Walker 1995) is highly specific and acceptably sensitive, but 
requires several hours of labor and an experienced pathologist. Nucleic acid detection by 
polymerase chain reaction (PCR) or real-time PCR is highly specific and acceptably 
sensitive for whole blood specimens but requires labor-intensive sample preparation 
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(Eremeeva et al. 2003; Jiang et al. 2003; Stenos et al. 2005). Special shell-vial cell culture 
assays have been developed for diagnosis of rickettsioses, but 4-15 days of culture in a 
BSL-3 facility is needed (Birg et al. 1999; La Scola and Raoult 1996; Quesada et al. 2006).
Here, we describe advancements in microfluidic biosensor technology addressing key 
requirements for high detection sensitivity and specificity, in a test format poised for rapid, 
simple and affordable use in point-of-care settings. As a proof of concept, we demonstrate 
detection of rickettsial organisms in complex biological samples including serum, blood and 
high backgrounds of non-targeted bacteria. We developed an immuofluorescence-based 
rickettsial detection assay using an antibody-coated macroporous polyacrylamide monolith 
(PAM) fabricated within a microfluidic channel to capture and concentrate bacteria from 
blood samples. Porous polymer monoliths have been explored for wide-ranging uses in 
microfluidic applications including filtration, pumping and chromatography (Namera et al. 
2011; Svec 2010; Vázquez and Paull 2010). Acrylamide-based monoliths were previously 
explored for capillary electrochromatography (Guryča et al. 2007; Palm and Novotny 1997; 
Svec 2010; Xie et al. 1997). Here, the antibody-functionalized PAM filter enables highly 
effective immunocapture and sensitive detection of rickettsial organisms in a flow-through 
format (Figure 1). The PAM exhibits low non-specific background from potentially 
interfering blood components and non-targeted bacterial species. Performance of the device 
is demonstrated using serum and blood samples spiked with known quantities of R. typhi 
and R. conorii. With spatially resolved fluorescent imaging, individual particles were 
counted with a detection limit of ~102 cells/ml and linear range up to over 105 cells/ml 
biofluid . A 10 μl sample can be analyzed in about 30 min and larger volumes processed if 
desired. For acute phase human rickettsioses, the range of rickettsial organisms found in 
blood circulation is not well defined. A significant technical concern in developing an 
actionable early diagnostic test is that blood sampling for acute phase diagnostics may 
require an assay detection limit of as few as ~10 bacteria in a relatively large volume of 
blood (~0.1 to 1 ml). The methods described were developed with the aim of meeting these 
potential sampling and high sensitivity requirements in addition to affordability, and 
usability criteria for point of care settings.
2. Material and methods
2.1 Reagents and materials
N,N’-methylenebisacrylamide (bisacrylamide), streptavidin acrylamide, and Alexa Fluor 
647 microscale protein labeling kit were from Invitrogen (Calsbad, CA). 40% Acrylamide 
solution, 3-(trimethoxysilyl)propyl methacrylate (98%), methylcellulose (MC), sodium 
phosphate, N-methylformamide (NMF), N,N’-diacryloylpiperazine (PDA), 
tetraethylthiuram disulfide (TED) and 2,2-dimethoxy-2-phenylacetophenone (DMPA), 
polyethylene glycol (PEG) 8000, Saponin, Atto 488-biotin, and glacial acetic acid were from 
Sigma (St. Louis, MO). 2,2’-Azobis[2-methyl-N-(2-hydroxyethyl) propionamide] 
photoinitiator (VA-086) was from Wako Chemicals (Richmond, VA). Urethane diacrylate 
(UDA) and triethyleneglycol dimethacrylate (TEGDMA) were from Sartomer (Exton, PA). 
PBS buffer (20X) was from Thermo Scientific (Rockford, IL). EZ-link NHS-PEG4-Biotin 
was from Thermo Scientific.
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Pressure sensitive adhesive (PSA) tapes were from 3M (St. Paul, MN). Glass cover slips 
were from Fisher Scientific (Pittsburg, PA). Glass fiber filter membranes were from 
Sterlitech (Kent, WA).
Heat-inactivated R. typhi and R. conorii were used in all the assays. To raise polyclonal 
rabbit anti-R. typhi and anti-R. conorii antibodies, New Zealand rabbits were immunized 
with 106 rickettsial organisms intravenously every 3 weeks until antibody titers by IFA 
reached 1:2,096. The rabbits were sacrificed humanely according to IACUC protocols and 
blood was harvested. Serum was separated by a low-speed centrifugation step (4,000 g) and 
purified using high affinity columns coated with protein G. Heat-killed Escherichia coli 
O157:H7 was purchased from KPL (Gaithersburg, MD). Healthy human serum and human 
blood was from Innovative Research (Novi, MI).
2.2 Device fabrication
A microfluidic channel layout was fabricated by photolithographic polymerization of 
urethane diacrylate (UDA) microchannels between two glass coverslips as shown in Figure 
2 and as previously described (Abhyankar and Hatch 2012). Two glass coverslips (24×40 
mm, No. 1.5, Fisher Scientific), one with channel via of 1 mm diameter holes cut using laser 
cutter, and the other without, were first cleaned with methanol and then spaced by two strips 
of 300 μm-thick double-sided pressure sensitive adhesive (PSA) tape at the edges. For a 
uniformed acrylate-silane coating on the glass surface to allow subsequent covalent linkage 
between glass and UDA, a mixture of 2:3:5 (v/v/v) 3-(trimethoxysilyl)propyl methacrylate, 
glacial acetic acid, and de-ionized water was pipetted into the space between the two glass 
coverslips and allowed to sit for 30 min inside a sealed container. The coverslips were then 
rinsed twice with methanol and twice with DI water, and dried with a vacuum.
UDA monomer mixture [48.75% UDA, 48.75% triethyleneglycol dimethacrylate 
(TEGMDA), 1.5% 2,2-dimethoxy-2-phenylacetophenone (DMPA) and 1% 
Tetraethylthiuram disulfide (TED)] was prepared with 4 h stirring and mixing enhanced via 
sonication for 30 min. The UDA monomer solution was pipetted into the 300 μm-thick 
cavity between the two glass coverslips through the via holes on the glass coverslip by 
manual pipetting. Black electrical tape with laser cut channel design was placed on the cover 
slip and served as a lithography mask. After illumination by a collimated UV light source 
centered at 365 nm at 25 mW/cm2 from a mercury lamp (OAI) (same setting for UV 
exposure as in the following steps) for 30 s, UDA channel wall was formed at the unmasked 
region inside between the coverslips. The uncured UDA monomer mixture in the masked 
regions (where the channels were) was removed by vacuum suction and the channels were 
rinsed with methanol, followed by UV post cure for another 40 s. The device and the 
channels were then cleaned with methanol and dried.
Our method for fabricating protein functionalized polyacrylamide monoliths extends upon 
earlier development of polyacrylamide monoliths (Guryča et al. 2007; Xie et al. 1997) 
formed from monomer solutions of buffered water/formamide/PEG/acrylamide. Here, we 
added photoinitiator to allow photolithographic patterning of the monolith in a microchannel 
and acrylamide streptavidin for simultaneous monolith functionalization for an 
immunoassay. The glass/UDA/glass channels were first filled with N-methylformamide 
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(NMF) for 1 min and then the polyacrylamide monolith monomer mixture [1 ml contained 
47.5 μl 40% acrylamide solution, 30 mg N,N’-diacryloylpiperazine (PDA), 30 mg 
Polyethylene glycol (PEG) 8000, 1 mg streptavidin acrylamide, 2 mg VA-086 
photoinitiator, and 950 μl NMF]. The channel openings were blocked with removable tape 
to prevent flow of monomer solution during photopolymerization of the PAM element via 
100 s UV exposure through the 2mm × 2mm mask window. After the uncured monomer 
mixture was removed, the channels were filled with deionized H2O and let sit for at least 2 h 
for complete release of uncured monomers from the PAM. The channels were further rinsed 
with deionized H2O and filled with 5% linear acrylamide polymerization mixture (5% 
acrylamide and 2 mg/ml VA-086 in H2O) and exposed under UV for 3 min to coat channels 
against non-specific adhesion of sample and reagent components.
We found PAM was effectively grafted to the silanized glass surface but not as well to the 
UDA edges. To enhance bonding of PAM to the UDA surface, an intermediate step was 
added; photopolymerization of a thin polyacrylamide gel on the UDA channel surface 
defined by a 2.0 × 0.5 mm window in the lithographic mask using a mixture of acrylamide/
bisacrylamide (8%T, 10%C) with 2 mg/ml VA-086 photoinitiator. With the elastic 
polyacrylamide gel on the UDA wall, the PAM monomers diffused into the polyacrylamide 
gel and polymerized both inside and outside the polyacrylamide gel and thus effectively 
graft onto the UDA surface through the polyacrylamide gel. The channel openings were 
sealed with removable tape to prevent flow during polymerization with 45 s UV exposure. 
Afterwards the channels were cleaned with deionized water and exposed to UV for 30 s post 
cure. The channels were then ready for PAM fabrication.
To post-functionalize PAM surface with a specific antibody, devices were filled with 5 μl of 
0.2 mg/ml biotinylated antibodies for 2 h at room temperature to ensure maximal binding of 
antibodies to the PAM through high-affinity streptavidin-biotin interaction. Antibody stock 
was biotinylated beforehand using EZ-link NHS-PEG4-Biotin following the manufacturer's 
instructions. The channels were then rinsed with PBS three times and the device was ready 
for use. A custom laser-cut PMMA manifold for coupling chips to pumps was attached onto 
the glass coverslip device using double-sided adhesive tapes. Device structure and images 
are illustrated in Figure 2.
2.3 Assay protocols
As shown in Figure 3, samples were loaded into the device by syringe pump (New Era 
Pump System, Farmingdale, NY) from port a to d. Human blood samples spiked with 
rickettsial organisms (concentration varied from 1×102 to 5×105 cell/ml) were processed by 
lysing using 4 volumes of 0.2% Saponin, vortexing for 5 s, and passing through a 15 mm-
long glass fiber filter membrane (1.5 μm pore size) prior to injection into the microchannel. 
A serum sample spiked with rickettsial organisms was loaded directly onto the device. 
Volumes from 10 to >100 μl can be processed depending on the concentration of targeted 
bacteria and the sensitivity required. In data shown in Fig. 5, a fixed sample volume of 60 μl 
was loaded for 30 min at 2 μl/min. PBS was subsequently pumped through port a to b for 5 
min at 20 μl/min to wash non-captured sample components away from the PAM. Reporter 
solution, 20 nM AF647-anti-R. typhi antibody, was then loaded from port a to b to fill the 
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channel including PAM immuno-capture interface and incubated for 10 min. Afterwards, 
unbound reporter antibody was rinsed with PBS injection from ports a and c to b at 20 
μl/min for 5 min.
Immunofluorescence results were measured by epifluorescence using a 5X objective lens 
and optical filter set for AF-647 fluorescence (excitation at 642 nm and emission at 705 nm) 
on an inverted fluorescent microscrope (Olympus). The lens was focused on the ~50 nL 
region of chips where targeted cells were captured at the front edge of PAM and stained by 
reporter antibody. Spatially resolved fluorescent images captured with a CCD camera 
(CoolSNAP HQ, Photometrics) were auto-analyzed using ImageJ software (http://
rsbweb.nih.gov/ij/). Processing included background subtraction and threshold intensity set 
to count particles. Fluorescence background was measured from the fluorescent image of the 
same region of interest in the unstained channels.
3. Results and discussion
3.1 Characterization of PAM device
The PAM device configuration addresses a long list of diagnostic test requirements for early 
detection of highly virulent pathogens in clinical settings including test speed, sensitivity, 
specificity, affordability and ease of use. The antibody-functionalized PAM serves as a 
tightly localized solid-phase support structure where ubiquitous solid-phase immunoassay 
chemistries can be applied for clinical and lab use. The microchannel format shown in 
Figures 1-3 helps overcome common mass-transfer limitations by convective transport of 
target organisms to the solid-phase surface and prolonged interaction with the surface due to 
size exclusion. Overcoming mass-transfer limitations in this manner is only effective if non-
specific interactions of interfering species and reporter molecules are mitigated as in the case 
here with the hydrophilic PAM surface chemistry. We developed the functionalizable PAM 
by copolymerizing acrylamide monomer with streptavidin acrylamide, enabling subsequent 
generic attachment of biotinylated antibodies to the porous monolith. An alternative option 
is to instead directly graft an antibody acrylamide during the initial PAM fabrication. PAM 
was fabricated inside a low-cost glass-polymer chip. The microchannels were first defined 
using patterned UV-polymerization of a 300 μm thick layer of urethane diacrylate 
sandwiched between two acrylate-silanized glass coverslips (Abhyankar and Hatch 2012). 
Under our current experimental conditions, this technique allows quick prototyping of 
microfluidic devices with critical features larger than 200 μm. PAM was fabricated inside 
the device with branching channels on either side for flexible delivery of different fluids 
including reporter reagents, buffer and waste to or away from the monolith.
Functionalization of PAM was performed by subsequent incubation of biotinylated capture 
antibodies. Figure 4A-B demonstrates strong fluorescent signal from a PAM after 
incorporation of fluorescent Atto 488-biotin molecules, as compared to the negative control 
PAM fabricated without streptavidin-acrylamide.
To characterize transport characteristics of the device, different size fluorescent beads were 
injected through the device with flow through the PAM at 2 μl/min. Beads flowed uniformly 
across the full width of the PAM element and no side wall leakage was observed, 
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demonstrating that the PAM was sufficiently grafted to the glass/UDA channel walls. A 
PAM filter with pore sizes small enough to exclude target bacteria is advantageous for 
focusing and concentrating the bacteria and facilitating rapid and efficient binding to the 
antibody-coated PAM surface. Larger pore sizes are advantageous to reduce pressure for a 
given flow rate, and help minimize clogging of pores or blocking of the reactive surface by 
non-targeted species in the sample. Optimizing for both criteria, the PAM monolith had a 
limiting pore size between 0.2- 1.0 μm, which is evaluated based on the passage of different 
size beads; 100 and 200 nm beads passed but not 1 μm beads as shown in Figure 4C-E. The 
slower flow rate of beads within the PAM than in the open channel results in a dramatically 
higher concentration of beads, even those that can pass through the monolith within the 
PAM under continuous flow (Figure 4C-D). In Figure 4E, 1 μm beads are clearly excluded 
and accumulate at the front edge of PAM. This pore size allows effective filtering of 
rickettsiae bacteria cells (1 μm × 4 μm) while permitting smaller particulates and 
macromolecules in serum or lysed blood sample to flow through, and maximizing the 
efficiency of immunoreactive capture of rickettsiae at the PAM surface.
3.2 Dose response of R. typhi detection
Serum and blood spiked with R. typhi were used as model biofluids for evaluation of device 
performance as the assay format was developed. The assay protocol is illustrated in Figure 3 
and described in Material and methods. The PAM functionalized with polyclonal anti-typhi 
antibodies captured the targeted rickettsial organisms with high efficiency, ~100%, as 
determined by fluorescence imaging. The captured R. typhi at the front edge of the PAM 
was stained with AF 647-labeled polyclonal anti-typhi antibodies. The imaged fluorescent 
particle count increased linearly with known concentrations of spiked cells. When target is 
below 100 cells, the captured R. typhi can be individually counted without too much overlap 
and within this range, the correlation between known concentrations and captured particles 
was ~1:1.
Typical fluorescent images of the PAM by the end of the assays are shown in Figure 5A-F. 
For samples with low concentration of rickettsiae, fluorescent particles of the labeled 
bacteria can be individually counted from the PAM images by automatic particle analysis 
software yielding results equivalent to manual counting, with detection limit at <10 
cells/100 μl. In Figure 5B, 7 fluorescent particles were identified for a condition where 6 
were expected on average; note that sampling from the known stock concentration does not 
allow exact prediction of the number of particles loaded for each assay. Figure 5C shows an 
example where 66 fluorescent particles were counted, where 60 were expected on average. 
Low non-specific fluorescent background as the backdrop to fluorescently stained particles 
allows accurate counting of particles by setting a fluorescent intensity threshold based on 
negative control. For samples with concentration over 1×104 cells/ml (667 cells loaded), 
captured fluorescent particles were not individually resolved in the fluorescent images. In 
these cases, estimated number of fluorescent particles was calculated from the total number 
of fluorescent pixels within the 100 μm × 25 μm detection window at the front edge of the 
monolith divided by an average fluorescent particle size. By this metric, the increase in 
fluorescent signals increased linearly with respect to rickettsiae concentration before the 
signal reaches a spatial saturation plateau above 105 cell/ml. (Figure 5G).
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Using an unfunctionalized PAM, only 78 rickettsiae cells were detected from 60 μl 1×105 
cells/ml sample where 6000 cells were loaded, corresponding to a 1.3% retention rate, 
presumably caused by non-specific trapping of the bacteria inside the porous polymer 
structure. The great majority of the rickettsial organisms (>98%) were rinsed away, 
indicating low-fouling property of the polyacrylamide backbone of PAM, which is 
important for highly sensitive and specific pathogen capture.
Although individual particles are effectively counted here with imaging, a simplified point 
detection scheme to measure the total fluorescence signal from the detection zone is 
desirable for more affordable and compact portable instrumentation when compared with a 
CCD imaging setup. The sensitivity of point detection is directly dependent on the level of 
non-specific background signal and size of the detection zone. To evaluate point detection, 
the averaged signal of the full detection zone encompassing the capture region at the front 
edge of the monolith (e.g., as illustrated in Figure 2C) is calculated from the fluorescent 
images and plotted as a function of target cells loaded in Figure 5H. Using the point 
detection method, the detectable level (calculated as background plus three times of noise 
variation) is increased compared to particle counting, but is still quite good at ~10 cells from 
60 μl lysed blood samplea and 25 cells from 60 μl serum samples. This excellent point 
detection sensitivity is attributed to the low non-specific background along with small zone 
of detection achieved with the hydrophilic monolith exclusion approach. When >10,000 
cells were captured, the fluorescent signal was saturated for the same detector settings as the 
surface of the PAM was densely covered by captured rickettsiae (Figure 5F).
3.3 R. typhi detection in lysed blood
Because Rickettsia is an intracellular parasite and may largely reside in circulating 
endothelial cells and white blood cells, a clinical whole blood sample may require lysing of 
circulating host cells to release the bacteria. We found that 4 volumes of 0.2% Saponin is 
effective in breaking up most of the blood cells while maintaining the basic structure of 
rickettsiae (Siddiqui et al. 1979), allowing subsequent immunofluorescent staining of the 
bacteria captured on the PAM. However, since there is still debris in the blood lysate, we 
found that a pre-filtering step using a glass fiber filter helped to prevent downstream 
clogging at the PAM assay filter. Dose response of R. typhi detection from whole blood is 
illustrated in Figure 5G-H. The results demonstrate fast and sensitive rickettsiae detection 
from whole blood using the PAM device with simple sample preparation steps of blood lysis 
with detergent and membrane filtering.
3.4 Specificity test with R. typhi, R. conorii and E. coli
To demonstrate the specificity of the assay for R. typhi detection, we performed assays 
using serum spiked with the same concentration (1×104 cells/ml) of R. typhi, R. conorii, and 
E. coli O157:H7 using the same anti-R. typhi functionalized PAM devices. The result shown 
in Figure 6 demonstrates that compared to equivalent levels of specific target, the signal 
drops 92% when the same concentration of related species R. conorii is present, and the 
signal drops to background noise when the same concentration of E. coli O157:H7 is 
present. The specificity of an individual assay element is largely dependent on the 
specificity of both the capture and the reporter antibody. In addition, the specificity of the 
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assay may also be further improved by optimizing the pore size to avoid non-specific 
trapping of particles and by more stringent rinsing. Furthermore, the layout of the 
microfluidic device can be expanded for multiplexed assays targeting several different 
related bacterial species simultaneously.
4. Conclusions
We have developed a polyacrylamide monolith-based fluidic device for detection of a SFG 
and TG rickettsiae in serum and blood samples. The porous hydrophilic monolith 
functionalized with anti-R. typhi antibody can effectively capture the bacteria from serum 
and blood specimen and allow subsequent immunofluorescent staining and imaging of the 
bacteria inside the chip. The assay can handle 10 to >100 μl of sample and high sensitivity 
can be achieved in about 30 min for 10 μl samples. The detection limit is ~102 cells/ml with 
~100% capture rate. Dynamic range of detection covers 4 orders of magnitude, from 100 
cells/ml to 5×105 cells/ml. This is a novel approach aiming towards a fully automated point-
of-care diagnostic system for rapid and sensitive detection of rickettsiae and other blood-
borne bacterial pathogens.
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Highlights
• Capturing bacteria via monolith in a micro-flow channel overcomes transport 
issues;
• Bacteria from blood volumes up to100 μl were captured and stained within 
minutes;
• Hydrophilic monolith offers low non-specific fouling, enhances detection 
sensitivity;
• Packing captured bacteria into microscale imaging area enhances detection 
sensitivity;
• Fewer than 10 Rickettsia typhi cells were detected in blood with ~100% capture 
rate.
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Figure 1. Schematic illustration of rickettsiae assay format
1. Polyacrylamide monolith (PAM) functionalized with anti-rickettsiae capture antibodies. 
2. As sample flows through the monolith, rickettsiae cells are excluded by smaller pore size 
and specifically captured by antibodies at the monolith edge. 3. Captured rickettsiae cells are 
stained by fluorescently labeled reporter antibodies. 4. Final rinse leaves fluorescently 
tagged rickettsiae for quantitative measurement.
Mai et al. Page 12
Biosens Bioelectron. Author manuscript; available in PMC 2016 January 14.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. Structure of the PAM microfluidic device
The channel layout (300 μm deep 2 mm wide) and PAM filter are sequentially formed by in 
situ photolithographic polymerization of polyurethane diacrylate and PAM between two 
glass coverslips. (A) Bright field device image. (B) Top view of the device layout. (C) 
Bright field image of the PAM edge. (D) Side view of the PAM structured inside the 
channel.
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Figure 3. 
Assay protocol for R. typhi detection from serum or filtered blood lysate sample.
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Figure 4. Characterization of PAM functionalization and pore size
(A-B) Pseudo-colored fluorescent images of plain PAM and functionalized PAM, which is 
co-polymerized with streptavidin acrylamide, after staining with fluorescent Atto 488-biotin. 
Strong fluorescence inside the functionalized PAM indicates successful integration of the 
streptavidin moiety. (C-E) Pseudo-colored fluorescent images of PAM when fluorescent 
beads of different sizes are injected from the upper side of the PAM. In C and D, 100 nm red 
and 200 nm orange fluorescent beads can flow through and stain the entire monolith. In E, 1 
μm green fluorescent beads are blocked at the front edge of the monolith.
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Figure 5. Dose response of R. typhi detection
(A-F) Pseudo-colored fluorescent images of the front edge of PAM after the assays with 60 
μl serum or lysed blood sample spiked with increasing concentration of R. typhi using PAM 
conjugated with anti-R. typhi antibodies. Fluorescent particles in figure B are highlighted 
with yellow circles. (G) Fluorescence imaging ananlysis comparing particle counts to 
number of cells expected in the loaded sample. (H) Simpler point-detection analysis; 
averaged fluorescent signal across the PAM region of interest vs. expected concentration of 
R. typhi in serum and lysed blood sample. Error bars are standard error of the mean from 
three independent experiments. The dotted line indicates the detection limit for lysed blood 
sample.
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Figure 6. Detection specificity
Averaged fluorescent signal from assays using serum sample spiked with 1×104 cells/ml R. 
typhi, R. conorii or E. coli O157:H7 with anti-R. typhi PAM and anti-R.typhi detection 
antibodies. Error bars are standard error of the mean from three independent experiments.
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